Ear wax may hold the key to early Parkinson's diagnosis
An unlikely body byproduct may be able to help doctors diagnose Parkinson's Disease early.
According to a new Chinese study, which was published in Analytical Chemistry, ear canal secretion, or ear wax, contain chemical compounds which can be telltale signs of Parkinson's.
During the study, researchers examined ear canal secretions from 209 people. About half (108 of the participants) had Parkinson's. In their examinations, scientists were able to identify four volatile organic compounds (VOC) that were notably different in those with the disease. Those compounds, or biomarkers, were ethylbenzene, 4-ethyltoluene, pentanal, and 2-pentadecyl-1,3-dioxolane.
The scientists then trained an artificial intelligence olfactory (AIO) system on the biomarker data. And once training was complete, the AIO system was able to successfully determine which patients had Parkinson's and which did not. The system was accurate 94% of the time.
Currently, Parkinson's is a tough disease to diagnose. According to Mayo Clinic, it requires expensive imaging, neurological tests, blood tests, genetic testing, and more. And often, a diagnosis is still often not conclusive. Likewise, treatment is a work-in-progress, with current therapies aimed at slowing progression rather than curing it. Therefore, ear wax testing could be a breakthrough first-step screening tool that's inexpensive, noninvasive, and accessible.
The researchers who worked on the study say the findings are a major step in Parkinson's early detection, which currently, doesn't exist, but that more research is needed. 'This method is a small-scale single-center experiment in China,' study coauthor Hao Dong said in a press release.
Hoa Dong continued, 'The next step is to conduct further research at different stages of the disease, in multiple research centers and among multiple ethnic groups, in order to determine whether this method has greater practical application value.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
Alzheimer's and Parkinson's charities identify new ways to reuse current drugs
Scientists are to examine whether drugs that are already in use could be repurposed to treat the symptoms of both Alzheimer's disease and Parkinson's in a new collaboration which aims to discover novel treatments at pace. Experts say that by repurposing drugs, they can 'increase the shots on target' at tackling the diseases. This method of drug development could also reduce the time patients are left waiting for new treatments by up to 10 years, they added. It comes after the NHS spending watchdog rejected the use of new Alzheimer's drugs lecanemab and donanemab for widespread use in the health service. The drugs were approved for use in the UK last year by the UK's medicines regulator but the NHS spending watchdog, the National Institute for Health and Care Excellence (Nice), said they could not be used in the NHS because the benefits are 'too small' to justify the cost. Now charities Cure Parkinson's and Alzheimer's Research UK have joined forces to find current drugs that may tackle some of the common biology behind both diseases. After presentations to the International Linked Clinical Trials (iLCT), which was set up by Cure Parkinson's over a decade ago, experts from both fields will select the most promising drugs for both Parkinson's and dementia, so they can be moved quickly into clinical trials. Weight loss jabs are already being investigated for their effectiveness in treating symptoms of both diseases and experts hope to uncover more drugs that can have multiple uses. Semaglutide, the active ingredient for weight loss and diabetes drugs Wegovy and Ozempic, is being examined in clinical trials to see whether it can help patients with Alzheimer's disease or Parkinson's. Trial results for the Alzheimer's trial are expected to be published later this year. Dr Sheona Scales, director of research at Alzheimer's Research UK, told the PA news agency that the iLCT project had already been 'hugely successful' with people who have Parkinson's, adding: 'Around 30% of disease modifying therapies that are in clinical trials for Parkinson's disease came through this process. 'What we wanted to do is to build on their knowledge and experience and expertise in order to be able to bring a process similar to that to Alzheimer's disease.' Dr Scales said that there are some 'common grounds' between Parkinson's and Alzheimer's – both are neurodegenerative diseases and have some 'common biological processes' – such as inflammation, mitochondrial dysfunction and 'protein misfolding' – which could be targets for repurposed drugs. 'Getting multiple drugs that are targeting the disease is really important to us,' she said. 'Testing different types of drugs and getting as many shots on target is important.' She said: 'Repurposed drugs have already been demonstrated to be safe for use in humans development of new drugs for different diseases is a long process. 'What essentially bringing repurposed drugs does, is help to accelerate the drug development pipeline – it could save between five and 10 years within that process, compared to taking a new drug through clinical trials for the very first time.' Helen Matthews, chief executive of Cure Parkinson's, said the iLCT was originally set up to identify drugs that can potentially 'slow down, stop or reverse Parkinson's'. She added: 'It was through this programme that we realised that there were so many drugs that were also being looked at in the dementia field and there were commonalities there in terms of the drugs looking to reduce inflammation, or whatever it might be, there were specific pathways that those drugs were working on that could be beneficial for both disease areas. 'So given that we were already doing the (work) every year, it made sense to join forces in this way, just to add efficiencies. 'Because if you're looking at the same drugs, we'll only do that digging once, you know, only do that compilation of the dossiers once, so that you can actually take the learning for both diseases and then actually look and see which might be beneficial.' She said that the 'sharing of knowledge and digging' could also be shared with other disease areas, such as MS. And on lecanemab and donanemab, Dr Scales added: '(These) were the first disease-targeting therapies that have been licensed in the UK, but obviously are not available on the NHS at the moment. 'They showed for the very first time that we were able to alter the course of the disease. 'And what we're looking forward to now is what the next generation of treatments can bring us and how we can target different parts of the disease.' Dr Lucy Devendra, head of research at Alzheimer's Society, said: 'Repurposing medicines which are already known to be safe can help us find new treatments for the diseases that cause dementia much quicker. 'Although it is still early days, it's encouraging to see a renewed focus on this type of research and development.'
Bloomberg
an hour ago
- Bloomberg
China Youths Find Hope in Spiritual Healing
Tarot readings, bazi consultations, and crystal healing are booming in China as disillusioned youth seek hope amid a sluggish job market and falling wages. In Beijing, bars and cafés now pair coffee or whiskey with fortune-telling sessions. The pan-mental health market is projected to reach $1.5 billion next year, according to Frost & Sullivan. But the rise of this 'superstition economy' is drawing scrutiny from authorities, Bloomberg's Minmin Low reports from Beijing. (Source: Bloomberg)
Yahoo
2 hours ago
- Yahoo
Scientists Scanned the Brains of Hardcore Gooners and Found Something Ominous
Watching a whole bunch of smut has some major side effects — and no, we're not just talking about stained bedsheets. In a new study published in the journal Frontiers in Human Neuroscience, researchers at the Chengdu Medical College in China found that people who watch a lot of pornography had lower cognitive performance and showed signs of neurological arousal akin to opioid addiction. It's new data in a swirling debate over whether watching porn — or how much — affects cognition, emotional regulation, and our relationships. The battle has raged on for years in academic journals, but has gained increasing prominence as a divisive political and social issue in recent years (complicating matters further, there's a broad medical consensus that masturbation is healthy.) The Chengdu researchers are squarely in the "porn sucks" category with this study. Using an experimental cohort of 21 heterosexual, mostly male college students — 16 who said in a survey they only watch adult content on occasion, and five who were described as having a "severe" internet porn addiction — the team used a brain imaging technique to measure how the habit was affecting cognition. Known as functional near-infrared spectroscopy or fNIRS, this imaging method looks at brain activity by shining a near-infrared light through the scalp and seeing how much of its light is absorbed by the hemoglobin in the brain. Using a fitted fNIRS cap and additional instruments that recorded facial expressions and vital signs, the researchers looked at the brain and body feedback coming from those 21 college students while they watched a 10-minute-long X-rated clip. Before and after the viewing session — in which the participants were asked to not masturbate, we should note — the students performed tests designed to measure cognitive function. The brain readings of the two groups turned out to be vastly different. The occasional porn watchers exhibited stronger neural connectivity in brain regions related to language, movement, and sensory processing. And the "gooners," to use cultural parlance for people who are seriously hooked on erotica, had heightened connectivity in regions related to executive function, addiction, and emotional regulation. The gooner squad also showed higher emotional and physiological arousal than their less-porn-watching counterparts, and their facial expressions when watching the clip showed a wide variety of emotions ranging from happiness to anger — though strangely, the study also found they appeared more "numb" than the lower-frequency group. In sum, the study suggests, the effects were similar to opioid users who experience intense calm, euphoria, and blurry perception. Physiologically, there were similarities between both groups during the viewing sessions — but the changes exhibited were often more dramatic in the gooners. Both groups had lowered heart rates during the session, but the effect was more pronounced in the more dedicated smut consumers. The same was true for the lowered cognitive performance both groups showed post-porn, which declined more steeply in the high-frequency porn watchers. These results aren't entirely surprising. A 2021 study found that problematic porn watchers suffer deficits in everything from working memory and decision-making to inhibition control and attention span; a 2014 paper found reductions in gray matter volume associated with consuming adult content. Though there will obviously need to be more and larger studies to figure out what's going on physically and neurologically with gooners, this research seems to demystify porn's effects on frequent watchers — not to mention an interesting new datapoint in the debate over the seriousness of porn addiction, too. More on porn: Government Website Caught Hosting "Gay Impregnation" Content
